scholarly journals Systemic Therapy in Pediatric-Type Soft-Tissue Sarcoma

2020 ◽  
Vol 27 (11) ◽  
pp. 6-16
Author(s):  
K.M. Ingley ◽  
S. Cohen-Gogo ◽  
A.A. Gupta
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Alternative Treatment ◽  
Systemic Therapy ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Targeted Agents ◽  
Soft Tissue Tumours ◽  
Cooperative Approach ◽  
Multi Agent

Soft-tissue sarcoma (sts) is rare and represents approximately 7% of cancers in children and in adolescents less than 20 years of age. Rhabdomyosarcoma (rms) is most prevalent in children less than 10 years of age and peaks again during adolescence (16–19 years of age). Multi-agent chemotherapy constitutes the mainstay of treatment for rms. In other non-rhabdomyosarcoma soft-tissue tumours, such as synovial sarcoma, evidence for routine use of chemotherapy is less robust, and alternative treatment options, including targeted agents and immunotherapy, are being explored. In this review, we focus on chemotherapy for pediatric-type rms and discuss the advances and challenges in systemic treatment for select non-rhabdomyosarcoma soft-tissue tumours in children and adolescents. We support an increasingly cooperative approach for treating pediatric and adult sts.

scholarly journals Chemotherapy in Pediatric-Type Soft-Tissue Sarcomas

2020 ◽  
Vol 26 ◽  
Author(s):  
K. M. Ingley ◽  
S. Cohen-Gogo ◽  
A. A. Gupta
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Alternative Treatment ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Soft Tissue Sarcomas ◽  
Targeted Agents ◽  
Soft Tissue Tumours ◽  
Cooperative Approach ◽  
Multi Agent

Soft-tissue sarcoma (STS) is rare and represents approximately 7% of cancers in children and in adolescents less than 20 years of age. Rhabdomyosarcoma (RMS) is most prevalent in children less than 10 years of age and peaks again during adolescence (16–19 years of age). Multi-agent chemotherapy constitutes the mainstay of treatment for RMS. In other non-rhabdomyosarcoma soft-tissue tumours, such as synovial sarcoma, evidence for routine use of chemo-therapy is less robust, and alternative treatment options, including targeted agents and immunotherapy, are being explored. In this review, we focus on chemotherapy for pediatric-type RMS and discuss the advances and challenges in systemic treatment for select non-rhabdomyosarcoma soft-tissue tumours in children and adolescents. We  support an increasingly cooperative approach for treating pediatric and adult STS.

scholarly journals Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease

2014 ◽  
Vol 37 (6) ◽  
pp. 355-362 ◽  
Author(s):  
Patrick Schöffski ◽  
Jasmien Cornillie ◽  
Agnieszka Wozniak ◽  
Haifu Li ◽  
Daphne Hompes
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Systemic Treatment ◽  
Advanced Disease ◽  
Treatment Options

scholarly journals Soft Tissue Tumours: Their Natural History and Treatment

1951 ◽  
Vol 44 (1) ◽  
pp. 19-36 ◽  
Author(s):  
Stanford Cade
Keyword(s):  
Soft Tissue ◽  
Natural History ◽  
Soft Tissue Sarcoma ◽  
Single Source ◽  
Soft Tissue Tumours ◽  
Results Of Treatment ◽  
Histological Confirmation

A series of 153 patients, the largest yet recorded from a single source, suffering from soft tissue sarcoma is discussed. References to the literature show the rarity of such tumours, the vagueness of the nomenclature and the disappointing results of treatment. Of the 153 patients only 7 have no histological confirmation of the diagnosis. In 146, sections and histological reports are available. 148 patients have been followed up either to death or to date.

scholarly journals Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin

2016 ◽  
Vol Volume 8 ◽  
pp. 95-104 ◽  
Author(s):  
Winette van der Graaf ◽  
Ingrid Desar ◽  
Anastasia Constantinidou ◽  
Suzanne Kaal ◽  
Robin Jones
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Critical Appraisal ◽  
Treatment Options ◽  
Advanced Soft Tissue Sarcoma

scholarly journals Update on Systemic Therapy for Advanced Soft-Tissue Sarcoma

2020 ◽  
Vol 27 (11) ◽  
pp. 25-33 ◽  
Author(s):  
A. Smrke ◽  
Y. Wang ◽  
C. Simmons
Keyword(s):  
Overall Survival ◽  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Systemic Therapy ◽  
English Language ◽  
Standard Of Care ◽  
Current Evidence ◽  
First Line ◽  
First Line Therapy

Background: Soft-tissue sarcoma (sts) represents a rare group of mesenchymal neoplasms comprising more than 50 heterogeneous subtypes. Great efforts have been made to increase the understanding of the treatment of advanced sts (unresectable or metastatic disease). We set out to determine whether outcomes for patients with advanced sts have improved over time and to assess the current evidence for systemic therapy. Methods: In a scoping review, we evaluated the contemporary evidence for systemic treatment of advanced sts in adults (>18 years of age). Phase i, ii, and iii studies of systemic therapy for advanced sts published in the English language were included. After abstract and full-text review of seventy-seven studies, sixty-two trials met the inclusion criteria. Results: The number of clinical trials conducted and published in advanced sts has increased over the last 30 years. Although median overall survival has increased, attempts at improving first-line therapy through dose intensification, doublet chemotherapy, or alternative backbones have not been successful. The optimal therapy beyond anthracyclines remains a challenge, especially given the heterogeneity that grouping multiple sts subtypes within clinical trials creates. However, increasing numbers of agents are being studied, and several studies had shown isolated benefit in progression-free or overall survival. Summary: First-line systemic therapy with an anthracycline remains the standard of care for advanced sts. However, choice of subsequent therapy beyond anthracyclines remains challenging. Novel systemic therapies, use of molecular diagnostics to direct therapy, subtype-specific trials, and learnings from real-world retrospective data are all important for improving outcomes in patients with advanced sts.

scholarly journals Next frontiers in systemic therapy for soft tissue sarcoma

2018 ◽  
Vol 7 (4) ◽  
pp. 43-43 ◽  
Author(s):  
Cheuh-Chuan Yen ◽  
Tom Wei-Wu Chen
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Systemic Therapy
Sign in / Sign up

Export Citation Format

Share Document